# NeoVolta Inc.: financial statements, quarterly

NEOV · Nasdaq · CIK 1748137 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/neov.md) · [Financials](/companies/neov/financials.md) · [Filings](/companies/neov/filings.md) · [Insiders](/companies/neov/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/neov/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.8](/filings/0001683168-24-007816.md) | [1.0](/filings/0001683168-25-000834.md) | [0.3](/filings/0001683168-25-003355.md) | [0.6 d](/filings/0001683168-25-007304.md) | [0.6](/filings/0001683168-25-008147.md) | [1.1](/filings/0001683168-26-001018.md) | [2.0](/filings/0001683168-26-003941.md) | [4.8 d](/filings/0001683168-26-007333.md) | [6.7](/filings/0001683168-25-008147.md) | [4.6](/filings/0001683168-26-001018.md) | [2.0](/filings/0001683168-26-003941.md) | [0.0 d](/filings/0001683168-26-007333.md) |
| Cost of revenue | $m | [0.6](/filings/0001683168-24-007816.md) | [0.8](/filings/0001683168-25-000834.md) | [0.1](/filings/0001683168-25-003355.md) | [0.6 d](/filings/0001683168-25-007304.md) | [0.5](/filings/0001683168-25-008147.md) | [0.7](/filings/0001683168-26-001018.md) | [1.5](/filings/0001683168-26-003941.md) | [4.2 d](/filings/0001683168-26-007333.md) | [5.1](/filings/0001683168-25-008147.md) | [3.9](/filings/0001683168-26-001018.md) | [1.1](/filings/0001683168-26-003941.md) | [1.2 d](/filings/0001683168-26-007333.md) |
| Gross profit | $m | [0.1](/filings/0001683168-24-007816.md) | [0.2](/filings/0001683168-25-000834.md) | [0.2](/filings/0001683168-25-003355.md) | [0.0 d](/filings/0001683168-25-007304.md) | [0.1](/filings/0001683168-25-008147.md) | [0.3](/filings/0001683168-26-001018.md) | [0.5](/filings/0001683168-26-003941.md) | [0.6 d](/filings/0001683168-26-007333.md) | [1.6](/filings/0001683168-25-008147.md) | [0.8](/filings/0001683168-26-001018.md) | [0.9](/filings/0001683168-26-003941.md) | [(1.1) d](/filings/0001683168-26-007333.md) |
| Research and development | $m | [0.0](/filings/0001683168-24-007816.md) | [0.0](/filings/0001683168-25-000834.md) | [0.0](/filings/0001683168-25-003355.md) | [0.0 d](/filings/0001683168-25-007304.md) | [0.0](/filings/0001683168-25-008147.md) | [0.0](/filings/0001683168-26-001018.md) | [0.0](/filings/0001683168-26-003941.md) | [0.1 d](/filings/0001683168-26-007333.md) | [0.1](/filings/0001683168-25-008147.md) | [0.1](/filings/0001683168-26-001018.md) | [0.4](/filings/0001683168-26-003941.md) | [1.0 d](/filings/0001683168-26-007333.md) |
| Operating income | $m | [(0.4)](/filings/0001683168-24-007816.md) | [(0.6)](/filings/0001683168-25-000834.md) | [(0.6)](/filings/0001683168-25-003355.md) | [(0.7) d](/filings/0001683168-25-007304.md) | [(1.0)](/filings/0001683168-25-008147.md) | [(0.9)](/filings/0001683168-26-001018.md) | [(1.4)](/filings/0001683168-26-003941.md) | [(1.4) d](/filings/0001683168-26-007333.md) | [(0.9)](/filings/0001683168-25-008147.md) | [(4.5)](/filings/0001683168-26-001018.md) | [(2.6)](/filings/0001683168-26-003941.md) | [(10.2) d](/filings/0001683168-26-007333.md) |
| Interest expense | $m | [0.0](/filings/0001683168-23-007984.md) | [0.0](/filings/0001683168-24-000845.md) | [0.0](/filings/0001683168-24-003236.md) | [0.0 d](/filings/0001683168-25-007304.md) | [(0.0)](/filings/0001683168-25-008147.md) | [(0.0)](/filings/0001683168-26-001018.md) | [0.1](/filings/0001683168-26-003941.md) | [0.2 d](/filings/0001683168-26-007333.md) | [(0.0)](/filings/0001683168-25-008147.md) | [(0.0)](/filings/0001683168-26-001018.md) | [0.1](/filings/0001683168-26-003941.md) | [0.0 d](/filings/0001683168-26-007333.md) |
| Net income | $m | [(0.4)](/filings/0001683168-25-003355.md) | [(0.6)](/filings/0001683168-25-003355.md) | [(0.6)](/filings/0001683168-25-003355.md) | [(0.7) d](/filings/0001683168-25-007304.md) | [(1.0)](/filings/0001683168-26-003941.md) | [(1.0)](/filings/0001683168-26-003941.md) | [(1.4)](/filings/0001683168-26-003941.md) | [(1.6) d](/filings/0001683168-26-007333.md) | [(1.2)](/filings/0001683168-26-003941.md) | [(5.5)](/filings/0001683168-26-003941.md) | [(3.0)](/filings/0001683168-26-003941.md) | [(11.7) d](/filings/0001683168-26-007333.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001683168-24-007816.md) | [(0.02)](/filings/0001683168-25-000834.md) | [(0.02)](/filings/0001683168-25-003355.md) | not reported | [(0.03)](/filings/0001683168-25-008147.md) | [(0.03)](/filings/0001683168-26-001018.md) | [(0.04)](/filings/0001683168-26-003941.md) | not reported | [(0.04)](/filings/0001683168-25-008147.md) | [(0.16)](/filings/0001683168-26-001018.md) | [(0.08)](/filings/0001683168-26-003941.md) | not reported |
| Basic EPS | $ per share | [(0.01)](/filings/0001683168-24-007816.md) | [(0.02)](/filings/0001683168-25-000834.md) | [(0.02)](/filings/0001683168-25-003355.md) | not reported | [(0.03)](/filings/0001683168-25-008147.md) | [(0.03)](/filings/0001683168-26-001018.md) | [(0.04)](/filings/0001683168-26-003941.md) | not reported | [(0.04)](/filings/0001683168-25-008147.md) | [(0.16)](/filings/0001683168-26-001018.md) | [(0.08)](/filings/0001683168-26-003941.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.8](/filings/0001683168-23-007984.md) | [1.5](/filings/0001683168-24-000845.md) | [1.0](/filings/0001683168-24-003236.md) | [1.0](/filings/0001683168-25-007304.md) | [0.4](/filings/0001683168-24-007816.md) | [0.3](/filings/0001683168-25-000834.md) | [0.5](/filings/0001683168-25-003355.md) | [0.8](/filings/0001683168-26-007333.md) | [0.9](/filings/0001683168-25-008147.md) | [0.2](/filings/0001683168-26-001018.md) | [11.5](/filings/0001683168-26-003941.md) | [22.2](/filings/0001683168-26-007333.md) |
| Current assets | $m | [6.2](/filings/0001683168-23-007984.md) | [5.7](/filings/0001683168-24-000845.md) | [5.2](/filings/0001683168-24-003236.md) | [4.7](/filings/0001683168-25-007304.md) | [4.2](/filings/0001683168-24-007816.md) | [4.0](/filings/0001683168-25-000834.md) | [5.7](/filings/0001683168-25-003355.md) | [6.7](/filings/0001683168-26-007333.md) | [8.4](/filings/0001683168-25-008147.md) | [7.8](/filings/0001683168-26-001018.md) | [22.2](/filings/0001683168-26-003941.md) | [32.8](/filings/0001683168-26-007333.md) |
| Total assets | $m | [6.2](/filings/0001683168-23-007984.md) | [5.7](/filings/0001683168-24-000845.md) | [5.2](/filings/0001683168-24-003236.md) | [4.7](/filings/0001683168-25-007304.md) | [4.2](/filings/0001683168-24-007816.md) | [4.0](/filings/0001683168-25-000834.md) | [5.7](/filings/0001683168-25-003355.md) | [6.8](/filings/0001683168-26-007333.md) | [8.4](/filings/0001683168-25-008147.md) | [10.1](/filings/0001683168-26-001018.md) | [25.7](/filings/0001683168-26-003941.md) | [53.6](/filings/0001683168-26-007333.md) |
| Current liabilities | $m | [0.0](/filings/0001683168-23-007984.md) | [0.0](/filings/0001683168-24-000845.md) | [0.0](/filings/0001683168-24-003236.md) | [0.1](/filings/0001683168-25-007304.md) | [0.3](/filings/0001683168-24-007816.md) | [0.3](/filings/0001683168-25-000834.md) | [1.5](/filings/0001683168-25-003355.md) | [3.5](/filings/0001683168-26-007333.md) | [5.7](/filings/0001683168-25-008147.md) | [3.7](/filings/0001683168-26-001018.md) | [2.7](/filings/0001683168-26-003941.md) | [6.7](/filings/0001683168-26-007333.md) |
| Total liabilities | $m | not reported | not reported | not reported | [0.1](/filings/0001683168-25-007304.md) | not reported | [0.7](/filings/0001683168-25-000834.md) | [1.9](/filings/0001683168-25-003355.md) | [3.9](/filings/0001683168-26-007333.md) | [6.3](/filings/0001683168-25-008147.md) | [5.1](/filings/0001683168-26-001018.md) | [3.5](/filings/0001683168-26-003941.md) | [14.1](/filings/0001683168-26-007333.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | [0.0](/filings/0001683168-25-007304.md) | not reported | [0.2](/filings/0001683168-25-000834.md) | [1.4](/filings/0001683168-25-003355.md) | [2.6](/filings/0001683168-26-007333.md) | [4.1](/filings/0001683168-25-008147.md) | [2.9](/filings/0001683168-26-001018.md) | [0.6](/filings/0001683168-26-003941.md) | [1.1](/filings/0001683168-26-007333.md) |
| Shareholders' equity | $m | [6.1](/filings/0001683168-25-003355.md) | [5.7](/filings/0001683168-25-003355.md) | [5.1](/filings/0001683168-25-003355.md) | [4.6](/filings/0001683168-26-007333.md) | [3.9](/filings/0001683168-26-003941.md) | [3.3](/filings/0001683168-26-003941.md) | [3.8](/filings/0001683168-26-003941.md) | [2.9](/filings/0001683168-26-007333.md) | [2.1](/filings/0001683168-26-003941.md) | [5.0](/filings/0001683168-26-003941.md) | [22.2](/filings/0001683168-26-003941.md) | [39.6](/filings/0001683168-26-007333.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(179)](/filings/0001683168-24-007816.md) | [(324) d](/filings/0001683168-25-000834.md) | [(485) d](/filings/0001683168-25-003355.md) | [(27.5) d](/filings/0001683168-25-007304.md) | [(593)](/filings/0001683168-25-008147.md) | [(858) d](/filings/0001683168-26-001018.md) | [(2,050) d](/filings/0001683168-26-003941.md) | [(924) d](/filings/0001683168-26-007333.md) | [(2,494)](/filings/0001683168-25-008147.md) | [(2,084) d](/filings/0001683168-26-001018.md) | [(3,579) d](/filings/0001683168-26-003941.md) | [(7,035) d](/filings/0001683168-26-007333.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.0](/filings/0001683168-23-007984.md) | [32.8](/filings/0001683168-24-000845.md) | [33.2](/filings/0001683168-24-003236.md) | [33.2](/filings/0001683168-24-007816.md) | [33.2](/filings/0001683168-25-000834.md) | [33.2](/filings/0001683168-25-003355.md) | [33.2](/filings/0001683168-25-008147.md) | [33.3](/filings/0001683168-26-001018.md) | [33.5](/filings/0001683168-26-003941.md) | [34.2](/filings/0001683168-25-008147.md) | [35.0](/filings/0001683168-26-001018.md) | [40.2](/filings/0001683168-26-003941.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 59,013,247 at 2026-09-23, from the cover of the [10-K filed 2026-09-23](/filings/0001683168-26-007333.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.